Kelly G Knupp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3337496/publications.pdf

Version: 2024-02-01

55 papers	2,407 citations	236612 25 h-index	223531 46 g-index
56 all docs	56 docs citations	56 times ranked	2345 citing authors

#	Article	IF	Citations
1	Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2019, 394, 2243-2254.	6.3	227
2	Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. Pediatric Neurology, 2017, 68, 18-34.e3.	1.0	207
3	Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy and Behavior, 2015, 45, 49-52.	0.9	201
4	Response to treatment in a prospective national infantile spasms cohort. Annals of Neurology, 2016, 79, 475-484.	2.8	182
5	Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain, 2017, 140, aww342.	3.7	174
6	Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens. JAMA Neurology, 2020, 77, 300.	4.5	152
7	Early-Life Epilepsies and the Emerging Role of Genetic Testing. JAMA Pediatrics, 2017, 171, 863.	3.3	125
8	Heterozygous HNRNPU variants cause early onset epilepsy and severe intellectual disability. Human Genetics, 2017, 136, 821-834.	1.8	66
9	International consensus on diagnosis and management of Dravet syndrome. Epilepsia, 2022, 63, 1761-1777.	2.6	62
10	Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia, 2016, 57, 1834-1842.	2.6	58
11	The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium. Epilepsia, 2017, 58, 2098-2103.	2.6	55
12	An Atmospheric Pressure Chemical Ionization MS/MS Assay Using Online Extraction for the Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine. Therapeutic Drug Monitoring, 2017, 39, 556-564.	1.0	53
13	Care Delivery for Children With Epilepsy During the COVID-19 Pandemic: An International Survey of Clinicians. Journal of Child Neurology, 2020, 35, 924-933.	0.7	48
14	Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia, 2017, 58, 123-127.	2.6	44
15	Treatment Strategies for Dravet Syndrome. CNS Drugs, 2018, 32, 335-350.	2.7	43
16	Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome. JAMA Neurology, 2022, 79, 554.	4.5	43
17	Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey. Epilepsy and Behavior, 2018, 80, 152-156.	0.9	39
18	The humanistic and economic burden of Dravet syndrome on caregivers and families: Implications for future research. Epilepsy and Behavior, 2017, 70, 104-109.	0.9	38

#	Article	IF	Citations
19	Lorcaserin therapy for severe epilepsy of childhood onset. Neurology, 2018, 91, 837-839.	1.5	37
20	Management of Infantile Spasms During the COVID-19 Pandemic. Journal of Child Neurology, 2020, 35, 828-834.	0.7	33
21	Current Treatment Strategies and Future Treatment Options for Dravet Syndrome. Current Treatment Options in Neurology, 2018, 20, 52.	0.7	31
22	Parental Perception of Comorbidities in Children With Dravet Syndrome. Pediatric Neurology, 2017, 76, 60-65.	1.0	30
23	Comparative Effectiveness of Levetiracetam vs Phenobarbital for Infantile Epilepsy. JAMA Pediatrics, 2018, 172, 352.	3.3	30
24	The direct and indirect costs of Dravet Syndrome. Epilepsy and Behavior, 2018, 80, 109-113.	0.9	28
25	Why West? Comparisons of clinical, genetic and molecular features of infants with and without spasms. PLoS ONE, 2018, 13, e0193599.	1.1	28
26	Immediate outcomes in early life epilepsy: A contemporary account. Epilepsy and Behavior, 2019, 97, 44-50.	0.9	27
27	Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennoxâ€“Gastaut syndrome, ESES: A functional framework. Epilepsy and Behavior, 2020, 111, 107287.	0.9	26
28	Infantile Spasmsâ€”Have We Made Progress?. Current Neurology and Neuroscience Reports, 2018, 18, 27.	2.0	25
29	Neuroimaging of Early Life Epilepsy. Pediatrics, 2018, 142, .	1.0	23
30	Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort. Neurology, 2021, 97, .	1.5	19
31	Initial Treatment for Nonsyndromic Early-Life Epilepsy: An Unexpected Consensus. Pediatric Neurology, 2017, 75, 73-79.	1.0	18
32	Sleep in Dravet syndrome: A parent-driven survey. Seizure: the Journal of the British Epilepsy Association, 2021, 85, 102-110.	0.9	18
33	Growth and endocrine function in children with Dravet syndrome. Seizure: the Journal of the British Epilepsy Association, 2017, 52, 117-122.	0.9	16
34	Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy. Neurotherapeutics, 2021, 18, 1524-1534.	2.1	16
35	Stiripentol for the treatment of seizures in Dravet syndrome. Expert Review of Clinical Pharmacology, 2019, 12, 379-388.	1.3	14
36	Simultaneous Quantification of 17 Cannabinoids by LCâ€“MS-MS in Human Plasma. Journal of Analytical Toxicology, 2022, 46, 383-392.	1.7	13

#	Article	IF	Citations
37	Crisis Standard of Care: Management of Infantile Spasms during <scp>COVID</scp>â€19. Annals of Neurology, 2020, 88, 215-217.	2.8	13
38	COVIDâ€19 vaccine in patients with Dravet syndrome: Observations and realâ€world experiences. Epilepsia, 2022, 63, 1778-1786.	2.6	13
39	Prospective evaluation of oral cannabis extracts in children with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2019, 72, 23-27.	0.9	12
40	Infantile Spasms: Opportunities to Improve Care. Seminars in Neurology, 2020, 40, 236-245.	0.5	11
41	Dravet syndrome: A quick transition guide for the adult neurologist. Epilepsy Research, 2021, 177, 106743.	0.8	11
42	Evolution of Infantile Spasms to Lennox-Gastaut Syndrome: What Is There to Know?. Journal of Child Neurology, 2021, 36, 752-759.	0.7	10
43	Infantile Spasms and Injuries of Prematurity: Short-Term Treatment-Based Response and Long-Term Outcomes. Journal of Child Neurology, 2017, 32, 861-866.	0.7	9
44	Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response. Global Pediatric Health, 2019, 6, 2333794X1882193.	0.3	9
45	Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy. Clinical Toxicology, 2020, 58, 124-128.	0.8	9
46	Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth. Epilepsy and Behavior, 2021, 122, 108212.	0.9	9
47	Pediatric epilepsy. Neurology: Clinical Practice, 2012, 2, 40-47.	0.8	7
48	Incidence of Hypertension Among Children Treated With Adrenocorticotropic Hormone (ACTH) or Prednisolone for Infantile Spasms. Journal of Child Neurology, 2020, 35, 215-220.	0.7	7
49	Diagnostic Delay in Epilepsy: the Scope of the Problem. Current Neurology and Neuroscience Reports, 2021, 21, 71.	2.0	7
50	Inequities in Therapy for Infantile Spasms: A Call to Action. Annals of Neurology, 2022, 92, 32-44.	2.8	7
51	Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. Clinical Pharmacokinetics, 2020, 59, 1005-1012.	1.6	6
52	Comparison of Cosyntropin, Vigabatrin, and Combination Therapy in New-Onset Infantile Spasms in a Prospective Randomized Trial. Journal of Child Neurology, 2022, 37, 186-193.	0.7	5
53	New-onset seizure survey of epilepsy centers in the United States. Epilepsy and Behavior, 2019, 101, 106579.	0.9	3
54	Medication selection, health services outcomes, and cost trajectories for Medicaid beneficiaries with infantile spasms. Epilepsy Research, 2021, 176, 106733.	0.8	3

#	Article	IF	Citations
55	The language of seizure identification: A qualitative investigation. Epilepsy and Behavior, 2022, 126, 108484.	0.9	2